Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $53.89.

A number of equities analysts have recently commented on VERA shares. Guggenheim raised their target price on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a research report on Monday, October 28th. Scotiabank started coverage on Vera Therapeutics in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $60.00 price target on the stock. JPMorgan Chase & Co. raised their price target on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a research report on Tuesday. Evercore ISI upgraded shares of Vera Therapeutics to a "strong-buy" rating in a research report on Monday, September 16th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $107.00 price target on shares of Vera Therapeutics in a research note on Tuesday, October 1st.

Vera Therapeutics Price Performance

VERA traded up $1.13 during trading on Thursday, reaching $49.07. 921,487 shares of the company traded hands, compared to its average volume of 911,014. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43. The company has a market cap of $2.69 billion, a P/E ratio of -21.69 and a beta of 1.03. The firm has a fifty day simple moving average of $41.08 and a 200 day simple moving average of $39.03. Vera Therapeutics has a 12-month low of $10.50 and a 12-month high of $50.78.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.06). On average, equities analysts forecast that Vera Therapeutics will post -2.57 EPS for the current year.

Insider Buying and Selling

In related news, Director Beth C. Seidenberg sold 1,177 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total transaction of $49,445.77. Following the completion of the sale, the director now directly owns 160,376 shares of the company's stock, valued at $6,737,395.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Vera Therapeutics news, CEO Marshall Fordyce sold 14,471 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $39.76, for a total value of $575,366.96. Following the completion of the transaction, the chief executive officer now directly owns 322,667 shares of the company's stock, valued at approximately $12,829,239.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Beth C. Seidenberg sold 1,177 shares of the business's stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total value of $49,445.77. Following the sale, the director now directly owns 160,376 shares in the company, valued at $6,737,395.76. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,398 shares of company stock valued at $4,376,163 over the last three months. 21.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Vera Therapeutics

A number of large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Vera Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock valued at $86,000 after acquiring an additional 350 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company's stock valued at $172,000 after purchasing an additional 688 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Vera Therapeutics by 14.4% during the 2nd quarter. Arizona State Retirement System now owns 9,907 shares of the company's stock worth $358,000 after purchasing an additional 1,250 shares during the last quarter. Ensign Peak Advisors Inc grew its holdings in shares of Vera Therapeutics by 13.5% during the second quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company's stock worth $425,000 after buying an additional 1,400 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Vera Therapeutics by 30.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company's stock valued at $272,000 after buying an additional 1,737 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.